First Line or First Switch: Risks and Benefits of High-Efficacy Therapies for Multiple Sclerosis

The treatment landscape of multiple sclerosis has evolved significantly since the first treatment was approved over 2 decades ago. Currently, an estimated 1 million people live with MS. This course will examine MS treatment approaches, highlighting current guidelines as well as the emerging evidence behind using highly effective disease modifying therapies as first line therapy.

Course summary
Course opens: 
Course expires: 
Please login or register to take this course.